Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

E.R.I.C. 2018 Meeting: Professor John Seymour on MBL (Monoclonal B-cell Lymphocytosis), a CLL (chronic lymphocytic leukemia)

In science and medicine, information is constantly changing and may become out-of-date as new data emerge. All articles and interviews are informational only, should never be considered medical advice, and should never be acted on without review with your health care team.

At the first International European Research Initiative on CLL (ERIC) meeting held in Barcelona, Spain, there was much talk about MBL or Monoclonal B-cell Lymphocytosis, a possible precursor to CLL.

I asked Dr. John Seymour of the PeterMac in Melbourne, Australia to explain the basic concepts.


  • All cancer including CLL is clonal, in other words, it is made up of identical cells.
  • If one has ≥5,000 monoclonal B-cells that are typical of CLL, then chronic lymphocytic leukemia can be diagnosed.
  • If one has < 5,000 monoclonal B-cells,  the diagnosis is MBL.
  • The clonal cells in both diagnoses are the same and the 5,000 value is admittedly arbitrary.
  • MBL consist of two groups:
    • Low-count MBL has blood B-cell counts <0.5x9 cells/liter.
    • High-count MBL has blood B-cell counts ≥0.5x9/L but <5×109/L.
    • Low-count MBL does not progress to malignant disease.
    • High-count MBL does progress at a rate of 1-2% per year.
  • Both MBL and CLL patients have impaired immunity that puts us at a higher risk for infections and cancer.
  • Even when diagnosed with CLL, many of us can have a normal life expectancy.

Please enjoy my interview from ERIC 2018 with Dr. John Seymour.

Here is a 2015 lecture that Dr. Kay gave on MBL and early care in CLL:

Thanks for watching and reading.

Brian Koffman MDCM (retired)